LSI

Summer vacations are winding down, but the LSI Alumni are still on a roll This week, #LSIAlumni raised new funding, appointed new executives, emerged from stealth, and much more on the road to LSI Europe '24. Your 60-second news recap: Backpack Healthcare — Hafeezah Muhammad → Received a $1.1M grant funded by the Maryland Community Health Resources Commission to provide vital support to students, families, and caregivers within Howard County Public Schools. CairnSurgical, Inc. — Dave Danielsen → Closed $4.5M in a Series A2 financing, led by Morningside Ventures. Diality — Osman Khawar → Announced the appointment of Dr. Jennifer Joe, MD as Vice President, Medical Affairs. Endovascular Engineering — Mike Rosenthal → Announced the appointment of Dan Rose as Chief Executive Officer. IKONA Health — Tim Fitzpatrick → Announced a collaborative study with Dialysis Education Services and Lifeliqe to evaluate the impact of Lifeliqe's virtual reality product on dialysis workforce training programs conducted by DES. → This partnership focuses on assessing the effectiveness of VR tools in improving training outcomes, with a particular emphasis on workforce engagement, recruitment, and retention. MAUI Imaging — Rick Altinger → Emerged from stealth and announced a $4 million contract with the Department of Defense. Minerva Surgical, Inc. → Announced the appointment of Darin Hammers as new CEO. Navigation Sciences — Alan Lucas → Selected as ‘Best Start-Up’ candidate by the Prix Galien Foundation. Nitinotes Surgical — Raz Bar-On → Announced the appointment of Lloyd Diamond as CEO. Proprio — Gabriel Jones → Announced the appointment of Bryan Humbarger as Chief Commercial Officer. Vascular Perfusion Solutions, Inc. — Rafael J. Veraza, PhD, MPH → Awarded a $160,000 seed grant from the Consortium for Technology & Innovation in Pediatrics (CTIP) Accelerator. Congratulations to the LSI Alumni who made major news this week.

AccurKardia is delivering clinical-grade ECG interpretation software, to cardiac monitoring companies, thereby expanding access to the benefits of remote cardiac care to millions of patients worldwide. Their flagship product, the AccurECG™ Analysis System is an FDA-cleared, cloud-based, device-agnostic, and fully automated electrocardiogram (ECG) interpretation software platform. The software provides an array of benefits, such as beat-by-beat analysis, ventricular/supraventricular ectopic beat detection, heart rate measurement, and automated interpretation of 13 different heart rhythms including sinus tachycardia, sinus bradycardia, atrial fibrillation, and atrial flutter, among others. The fully automated output of AccurECG™ improves clinicians’ review efficiencies and enables prompt treatment of patients, with results delivered in minutes. It is indicated for adults aged 22 and older. AccurKardia has achieved many major milestones recently including: • Closed a $2.7 million Seed round • Received FDA 510(k) approval for AccurECG™ Analysis System • Selected to join Cohort 3 of Mayo Clinic Platform_Accelerate a program that provides access to Mayo Clinic's rich, de-identified data sets, validation frameworks, clinical workflow planning, and mentorship • Announced its first commercial partnership with Lucem Health, a leading provider of clinical AI solutions. • Announced the appointment of Moin Hussaini as Chief Product Officer • Announced the appointment of LSI Alumni, Ken Nelson, and Francisco Martorell as Senior Advisors To catch the latest from AccurKardia, tune into Juan C Jimenez and Moin Hussaini’s Studio Interview and presentation from LSI USA ‘24 to learn more about AccurKardia’s recent progress. Available on our website and YouTube channel.

How much weight should be placed on intellectual property protection for Medtech startups? In this clip, Sabing Lee, stresses the importance for early-stage companies to file patents as early as possible to demonstrate to investors that they have obtained some meaningful intellectual property protection. The panelists also discuss how IP is not the only thing early-stage companies should be focused on. Building a strong IP portfolio should be part of a broader strategy that includes securing regulatory approvals and developing robust operational capabilities. Tune into the full LSI USA ‘24 panel, “IP: Friend or Foe in Building Medtech Ventures?” to hear more from the panelists on this nuanced discussion. Hear from: • Irfan Lateef (Moderator) — Knobbe Martens • Leah Brownlee — Lazurite • Sabing Lee — Knobbe Martens • David Beylik — Ajax Health

INNOVENTRIC is at the forefront of addressing tricuspid regurgitation (TR), a condition affecting over 4.5 million people in the U.S. and Europe. Tricuspid regurgitation (TR) is a condition where blood flows back from the right ventricle into the right atrium, causing venous congestion and reduced cardiac output. Traditional treatment options are limited—medications only alleviate symptoms, and open-heart surgery, with its high mortality rates, is rarely offered. Enter Innoventric's Trillium™ device, a groundbreaking minimally invasive solution. The Trillium device utilizes cross-caval anchoring and a multi-valve design to fit various anatomies, offering a safe and reliable alternative without the risks of migration and leaks. What sets Innoventric apart is its ability to treat the entire patient population, including those ineligible for other treatment options due to large anatomies, pacemaker-induced TR, or previous failed procedures. To learn more about Innoventric, visit our website to watch Amir Danino’s full presentation from LSI USA ‘24—available on our website and YouTube channel. You can also meet with Amir at LSI USA ‘25 on March 17th - 21st in Dana Point, California.

What does the Medtech financing market look like in Europe? In our latest LSI Europe ‘24 panel, "Medtech Financing in Europe: Current State and Insights from Successful Raises," we’ll dive into two successful 2024 raises from leading European companies, Amber Therapeutics and ONWARD Medical. We’ll hear directly from both innovators and investors about what it takes to secure capital in Europe in 2024. This panel will explore: • The fundraising journeys of Amber Therapeutics and ONWARD Medical, including the challenges they faced and the key factors that contributed to their successful raises. • Insights from EQT Life Sciences on the current Medtech investment landscape and how companies can position themselves to attract capital. • Practical advice for Medtech companies looking to navigate the European financing market in 2024 and beyond. We’ll hear from: • Roger Brooks (Moderator) — RBrooks Group • Drew Burdon — EQT Life Sciences • Dave Marver — ONWARD Medical • Aidan Crawley — Amber Therapeutics Join us at #LSIEurope24 this September 16-20th to see more panel sessions like this and connect with hundreds of global Medtech and Healthtech leaders in Sintra, Portugal. Apply on our website today while space is still available.

Nina Capital will be joining us in full force at LSI Europe ‘24 next month. Nina Capital is a specialized venture capital firm investing exclusively at the intersection of healthcare and technology. They maintain an international outlook from their home in Barcelona and actively seed and support need-driven founders committed to improving healthcare with the help of technology. They invest in healthcare tools (solutions designed to help healthcare organizations be better at what they do) and medical devices (solutions intended for use in the diagnosis, cure, mitigation, prevention, or treatment of a disease). Nina Capital invests at the preseed and Seed stages and follow-on in select portfolio companies as they reach Series A readiness. They invest across Europe, the United Kingdom, the United States, Canada, Israel, and Australia. Nina Capital has invested in over 45 companies across 2 funds including companies like: • Methinks AI (Pau Rodríguez - #LSIAlumni) • Noah Labs (Oliver Piepenstock (ex Weiss)) • Subtle Medical (Enhao GONG) • Virtue Health Group (Robert Orford) • among others We’re thrilled to welcome Marta G. Zanchi, Aline Noizet, Nadine Y.N, and Yahel Halamish to LSI Europe '24 this September 16-20th in Sintra, Portugal. Want to see what other investors are joining us at LSI Europe ‘24? Head over to our website to see a preview.

Ebenbuild, a Munich-based startup, is revolutionizing the treatment of acute respiratory distress syndrome (ARDS) through AI and physics. The company's proprietary software creates digital twin models of patients' lungs using computer tomography and AI. These models enable personalized and precise mechanical ventilation, helping physicians manage lung stress and reduce complications. Traditional methods rely on patient body weight, often leading to suboptimal results. Ebenbuild’s approach considers individual lung physiology, predicting harmful ventilation settings and allowing safer, customized adjustments. This innovation reduces the frequency of ventilator adjustments, saving time, costs, and ultimately shortening the duration of artificial ventilation. Beyond ventilation, Ebenbuild is expanding its technology to drug research, aiming to optimize drug efficacy in lung treatment. By predicting how drugs will affect specific lung areas, the technology could enhance clinical trials, reduce costs, and improve patient outcomes. We’re excited to announce that CEO, Kei Wieland Müller has been selected to present Ebenbuild at LSI Europe ‘24 this September 16-20th in Sintra, Portugal. Join us in Portugal to meet with Kai and learn more about Ebebuild.

CairnSurgical, Inc. (#LSIAlumni) closed a $4.5 million Series A2 financing, led by Morningside Ventures. The company will use these new funds to complete the currently-enrolling U.S. pivotal trial of its Breast Cancer Locator (BCL™) System and implement a limited commercial launch of the technology in select European markets. Current Breast Conserving Surgery (BCS) fails to remove the entire tumor about 20% of the time, primarily because current breast tumor localization techniques do not provide the information required to achieve precise removal of the entire tumor. Cairn’s BCL System is designed to improve the accuracy of breast-conserving surgery (lumpectomy) by providing critical information about the tumor to the surgeon, including size, shape, and precise location. Congratulations to LSI Alumni Dave Danielsen and the entire Cairn Surgical team on this major milestone! To learn more about Cairn Surgical, connect with Dave Danielsen at LSI Europe ‘24 this September in Sintra, Portugal, where he will present the latest updates on Cairn.

We're just 4 weeks away from LSI Europe '24, but the buzz is already building amongst leading investors, strategics, and innovators for LSI USA '25 in Dana Point, California. After reviewing applications from global leaders working to build breakthrough Medtech and Healthtech businesses, we're revealing the first 100 Innovators selected to present at the event March 17th - 21st in 2025. Here's a sneak peek at 10 of them: • Jamal Rushdy — Arcuro Medical • Jenny Hoffmann, PhD — Biorithm • James Dacombe — CoMind • Danguole Altman — Cx Precision Medicine, Inc. • Chris Barron — EMBioSys • Codi Amir Gharagouzloo, Ph.D — Imaginostics • Yoonho Kim — Magnendo Corp. • Theadora James, MHA — Navigate Maternity • Chris Wood — Reveal-Dx • Alex Jiao — Scout Stay tuned for more innovator and investor announcements, and get in touch with our team to secure your spot at LSI USA '25. Our hotel room block at the Monarch Beach Resort is already nearing capacity and is expected to sell out well in advance. Secure your spot today to ensure you get the best rate and secure a hotel room onsite before they’re sold out.

We’re excited to announce a new Fireside Chat at LSI Europe ‘24: "SIA Story: The Good, the Bad, and the Ugly of M&A." This session will serve as a case study on the acquisition of SIA by Integra LifeSciences, offering an inside look at the real-life experiences of those who were at the heart of this deal. The conversation will cover the full spectrum of M&A, from strategic considerations and the ideal characteristics of an acquisition target to the challenges of managing relationships and navigating the acquisition process. SIA (Acquired by Integra LifeSciences) Co-Founders Alexei Mlodinow and Todd Cruikshank, along with Lauren Lacagnino, Sr. Director of Strategy & Business Development at Integra LifeSciences, will discuss key moments that shaped the deal, share insights on timing and market influences, and offer lessons learned that are valuable for anyone involved in the M&A process. This Fireside Chat is scheduled for September 18th at 7:00 pm at LSI Europe ‘24 in Sintra, Portugal. Interested in speaking, presenting, or exhibiting at LSI Europe '24? Join hundreds of global Medtech and Healthtech leaders in Sintra, Portugal this September 16-20th. Apply on our website today while space is still available.